1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63F1CE1E6D578BB84002589720027B676
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-driven-growth-maximizing-patient-journey-maps-co-creation?opendocument
18
19opendocument
2018.206.48.243
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Patient Focused Services Patient-Centric Initiatives

Patient-Driven Growth: Maximizing Patient Journey Maps & Patient Co-Creation

ID: POP-362


Features:

36 Info Graphics

36 Data Graphics

600+ Metrics

48 Narratives


Pages: 80


Published: 2023


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
As patients are taking an active role in their healthcare decision-making process, pharma organizations are taking rapid steps to become more patient-centric. Among the many patient-centric solutions and strategies, patient journey mapping and patient co-creation are important ways for pharma to listen to the patient voice and gain critical insights.

Forward-looking companies resort to patient journey mapping to tap into a patient’s experience through a disease, from the onset of symptoms to diagnosis, treatment, and management. This understanding is further augmented by establishing co-creation and involving patients early at each stage – whether it is at R&D stage for the creation of lay summaries, developing a new drug or treatment, or co-developing education and support resources.

Best Practices, LLC undertook this benchmarking research to help biopharma leaders improve patient-centric growth by probing innovative approaches, successful practices, and recommended vendors which are delivering high impact across patient journey mapping and patient co-creation. This report delivers insights around patient journey mapping capabilities, structure, staffing, high-impact areas, sources, validation, updates, automation, vendors, innovation and KPIs – and overall leadership support of patient-centric initiatives. It also establishes benchmarks around patient co-creation programs, key design phases, engagement channels, high-impact areas, and innovative trends.

Video Brief:

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alkermes; Astellas; AstraZeneca; Bayer; BELLUS Health; Biogen; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; CSL Behring; Debiopharm; Eli Lilly and Company; GlaxoSmithKline ; Janssen; Jazz Pharmaceuticals; Kala Pharmaceuticals; Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis; Novo Nordisk; Organon; OTSUKA; Pfizer; Sanofi; Sunovion; Takeda Pharmaceuticals; UCB Pharma

Study Snapshot

Best Practices, LLC engaged representatives from 26 biopharma manufacturers in this benchmark research study. To enhance the quality of research insights, nine qualitative interviews were conducted with high-performing benchmark participants.

Key topics covered in this report include:

  • Patient Journey Mapping Capabilities, Structure, and Staffing
  • Patient Journey Mapping Sources, Impact, and Validation
  • Patient Journey Mapping Tools, Updates, and Automation
  • KPIs to Measure Patient Journey Mapping Capability
  • Vendors for Innovative Patient Journey Approaches
  • Use of Patient Co-creation Programs
  • Effective Channels for Co-creation
  • Frequency of Co-Creation Insights Utilization

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Pull Through of Patient Journey Maps: Effective pull through of patient journey maps is driven by top-down support and patient measurement component for all teams.
  • Value Fronts for Patient Co-Creation: Top-rated value fronts for co-creation include #1 Improving digital health tools (wearables, adherence, biomonitoring, apps), #2 Identify pain points, and #3 Improving customer experience design.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 3-19
II.
Maximizing Patient Journey Map CapabilitiesPg. 20-48
III.
Maximizing Patient Co-CreationPg. 49-64
IV.
APPENDIX A: Study Participants & Data SummaryPg. 65-73
V.
APPENDIX B: Additional Voices from the FieldPg. 74-79
VI.
About Best Practices, LLCPg. 80

    List of Charts & Exhibits

    I. Executive Summary

    • Key insight on patient centricity
    • Key insight on pull through of patient journey maps
    • Key insight on staffing dedicated to patient journey maps
    • Key insight on maximizing patient journey mapping capability with dedicated patient insights group
    • Key insight on clinical support
    • Key insight on building patient journey maps
    • Key insight on KPIs for assessing PJM capabilities
    • Key insight on using innovative patient segmentation
    • Key insight on patient co-creation impact
    • Key insight on co-creation usage
    • Key insight on external partnerships

    II. Maximizing Patient Journey Map Capabilities

    • Hallmarks of patient centricity
    • Interview narrative on the reasons for having a patient centric organization
    • Interview narrative around steering committees
    • Teams and resources used by benchmark organizations to support each facet of the overall patient journey mapping capability
    • Teams and resources used by benchmark organizations to build journey maps and to provide insights
    • Teams and resources used by benchmark organizations to take actions on maps and to manage pull through of maps
    • Interview narrative around internal storytelling
    • Interview narrative around internal teams
    • Approximate number of employees working on building patient journey maps across the entire organization
    • Approximate number of employees working on building patient journey maps across the entire organization – High patient-centricity vs. Mid patient-centricity vs. Low patient-centricity segment
    • Top sources for building patient journey maps
    • Steps taken by benchmark organizations to validate the patient journeys built
    • Level of impact of patient journey maps in strategic planning
    • Interview narrative around patient journey mapping insights
    • Interview narrative around how journey maps can aid patient-driven trial design
    • Level of impact of patient journey maps in tactical customer engagement
    • Interview narrative around an integrated customer experience improvement system
    • Level of impact of patient journey maps in innovation
    • Reasons why benchmark organizations update a patient journey map
    • Interview narrative around improvements to patient journey maps
    • Automated journey mapping tools or platforms used at benchmark organizations to update patient journey maps
    • KPIs used by benchmark organizations to measure the success of their patient journey mapping capability
    • Percentage of companies using KPIs to measure patient journey mapping capability; Average number of KPIs used to measure patient journey mapping capability – High patient-centricity vs. Mid patient-centricity vs. Low patient-centricity segment
    • Interview narrative around measuring patient journey mapping capability
    • Interview narrative around return on investment on patient journey maps
    • Interview narrative around groups who make an impact
    • Recommended patient journey mapping tools
    • Vendors recommended for innovative patient journey approaches

    III. Maximizing Patient Co-Creation

    • Use of patient co-creation in the development of new initiatives
    • Interview narrative on co-creation and patient insights
    • Interview narrative around communicating patient voice
    • Commitment to patient co-creation
    • Interview narrative around clinical trials
    • Co-creation management
    • Interview narrative around sourcing co-creation
    • Effective channels for directly interacting and collaborating with patients to co-create new solutions
    • Utilization of co-creation insights for strategic planning
    • Utilization of co-creation insights for tactical customer engagement
    • Utilization of co-creation insights for innovation
    • Co-creation success stories
    • Frequency of co-creation insights utilization for strategic or tactical decisions
    • Frequency of co-creation insights utilization for strategic or tactical decisions – High patient-centricity vs. Mid patient-centricity vs. Low patient-centricity segment
    • Interview narrative around evaluating new programs

    IV. APPENDIX A: Study Participants & Data Summary

    • Research overview: Objectives, methodology and participants
    • Participant job titles
    • Therapeutic areas represented in the study
    • Key benchmark findings: Hallmarks of patient centricity; Patient journey mapping capability; Staffing; and Patient journey mapping sources
    • Key benchmark findings: Validation and Pull through impact
    • Key benchmark findings: KPIs and Updates, automation & tools
    • Key benchmark findings: Use of patient co-creation; Co-creation management; and Collaboration channels
    • Key benchmark findings: Patient co-creation utilization and Frequency of use

    V. APPENDIX B: Additional Voices from the Field

    • Interview narrative around increasing the accuracy of patient journey maps
    • Interview narrative around integrating patient voice into modern clinical trial design
    • Interview narrative around map building and utilization
    • Interview narrative around drawing medical society insights
    • Interview narrative around utilizing the right data sources and groups to build the patient journey